FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
Alimera Sciences, Inc., (Nasdaq: ALIM) today announced that it has received a complete response letter from the U.S. FDA in response to the New Drug Application for ILUVIEN for the treatment of diabetic macular edema associated with diabetic retinopathy.
The FDA stated that it was unable to approve the ILUVIEN New Drug Application because the New Drug Application did... More

